BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
Rhea-AI Summary
BriaCell (Nasdaq: BCTX) added NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center as a clinical site in its pivotal Phase 3 Bria-ABC study for advanced metastatic breast cancer. The trial evaluates Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice, with overall survival as the primary endpoint and an interim analysis planned after 144 patient events. Bria-IMT has received FDA Fast Track designation. ClinicalTrials.gov identifier: NCT06072612.
Positive
- Added NYU Langone Perlmutter as a Phase 3 clinical site
- Bria-IMT has FDA Fast Track designation
- Interim analysis planned after 144 patient events (clear trigger)
Negative
- Interim analysis requires 144 deaths to occur before readout
- No interim efficacy or survival results disclosed yet
News Market Reaction – BCTX
In the May 7 session, BCTX declined 1.20%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | ASCO data plans | Positive | +3.9% | Announced six Bria-IMT metastatic breast cancer data presentations at ASCO 2026. |
| Apr 20 | AACR QOL/biomarkers | Positive | -9.3% | Reported preserved quality of life and promising biomarker signals in Phase 3/2 studies. |
| Dec 18 | Nature Medicine feature | Positive | +3.2% | Phase 3 Bria-IMT trial named among 2026-shaping studies in Nature Medicine article. |
| Dec 10 | SABCS Phase 2/3 data | Positive | -7.9% | Shared Phase 2 survival and Phase 3 safety/biomarker data at SABCS 2025. |
| Dec 09 | Phase 3 enrollment | Positive | -2.1% | Confirmed Phase 3 enrollment on track with interim OS analysis planned upon 144 events. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial headlines for Bria-IMT/Bria-ABC often generate mixed or negative next-day moves despite generally positive clinical messaging, with more divergences than alignments.
Over the last few months, BriaCell has repeatedly highlighted progress in its Bria‑IMT pivotal Phase 3 program and related platforms. Clinical‑trial news on Dec 9–18, 2025 covered enrollment progress, Nature Medicine recognition, and Phase 2/3 data, yet price reactions were often negative. More recent clinical updates in April 2026 around AACR and ASCO presentations again showed mixed stock responses. Today’s addition of a major NYU site extends that ongoing Phase 3 execution story.
Key Terms
pivotal phase 3 medical
immune check point inhibitor medical
overall survival (os) medical
fast track designation regulatory
clinicaltrials.gov regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center, a renowned cancer center in New York City, as a clinical trial site in its ongoing pivotal Phase 3 clinical study (Bria-ABC).
BriaCell has enjoyed a marked uptick in interest from premier cancer centers and patient enrollment numbers following the prominent independent feature of its Phase 3 clinical trial in Nature Medicine’s publication, “Eleven clinical trials that will shape medicine in 2026”, linked here.
BriaCell’s pivotal Phase 3 clinical study in Advanced Breast Cancer (Bria-ABC) is evaluating BriaCell’s lead clinical candidate, Bria-IMT™, plus an immune check point inhibitor versus treatment of physician’s choice in advanced metastatic breast cancer.
“At NYU Langone Health’s Perlmutter Cancer Center, we are dedicated to offering state-of-the-art treatments to patients with difficult-to-treat cancers,” stated Nancy Chan MD, Director, Breast Cancer Clinical Research, NYU Langone Health’s Perlmutter Cancer Center. “We look forward to helping accelerate the development of Bria-IMT, a novel immunotherapy with the potential to improve outcomes for patients with advanced metastatic breast cancer.”
“We are thrilled to partner with clinical experts at the renowned NYU Langone Health’s Perlmutter Cancer Center, a patient-focused, NCI-designated Comprehensive Cancer Center, to further expand patient access to our novel immunotherapy treatment,” said Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We continue to advance the study and look forward to sharing interim data in the coming months.”
Interim analysis of the pivotal Phase 3 study will be conducted after 144 patient events (deaths) have occurred, with overall survival (OS) as the primary endpoint. The study compares the Bria-IMT combination regimen with immune checkpoint inhibitor versus physician’s choice in patients with advanced metastatic breast cancer. Importantly, the Bria-IMT combination regimen has been granted FDA Fast Track designation, underscoring its potential to address a serious unmet medical need.
For additional information on BriaCell’s pivotal Phase 3 study, please visit ClinicalTrials.gov NCT06072612.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the addition of a new clinical site in the ongoing pivotal Phase 3 clinical study of Bria‑IMT, and expectations regarding patient enrollment, interim analysis timing and the potential clinical benefits of the Bria‑IMT combination regimen, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
